United States· US:0069-2299_cf672c83-c9d9-4107-bcf1-76d4106537cc
Vizimpro
A medicinal product containing dacomitinib, registered in United States by Pfizer Laboratories Div Pfizer Inc.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- dacomitinib
- Manufacturer
- Pfizer Laboratories Div Pfizer Inc
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 1
- ndc11006922993030 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0069-2299-30)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Dacomitinib in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumVizimpro 45 mgPfizer Europe MA
- CzechiaVIZIMPROPfizer Europe MA EEIG, Bruxelles
- SpainVIZIMPRO 45 MG COMPRIMIDOS RECUBIERTOS CON PELICULAPfizer Europe Ma Eeig
- FinlandVizimproPfizer Europe MA EEIG
- IrelandVizimpro 45 mg Film-coated tabletPfizer Europe MA EEIG
- IcelandVizimproPfizer Europe MA EEIG*
- NetherlandsVizimpro 45 mg filmomhulde tablettenPfizer Europe MA EEIG
- NorwayVizimproPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vizimpro
- Liechtenstein · Vizimpro
- Norway · Vizimpro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/94b80589-600c-4b03-b787-c07d884dee1f GET /v1/drugs/94b80589-600c-4b03-b787-c07d884dee1f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": 5
},
"productid": "0069-2299_cf672c83-c9d9-4107-bcf1-76d4106537cc",
"productndc": "0069-2299",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "DACOMITINIB",
"proprietary_name": "Vizimpro",
"active_ingred_unit": "mg/1",
"application_number": "NDA211288",
"marketing_category": "NDA",
"nonproprietary_name": "dacomitinib",
"start_marketing_date": "20181004",
"active_numerator_strength": "45"
}See everything about dacomitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.